Anton Bittner

Anton Bittner is Program Director at Ryne Bio. He has extensive experience as a program manager, leading development teams to three INDs and two drug approvals in both US and EU. He has over 20 years of experience as a drug discovery scientist, leading the functional genomics team at Janssen R&D in La Jolla, CA, supporting the development of genomic tools to provide orthogonal measures of ADME, PK, and toxicology and has 25 peer-reviewed publications. Over the past 8 years, he has worked on drugs for 4 different orphan indications, including the CMC process development stage of Rylaze, now approved for the treatment of pediatric ALL. He has also led biosimilar product development, enabling treatment for patients that would otherwise not have access to disease altering therapy. Through this work, a biosimilar teriparatide was approved in both the US and EU, as well as in additional countries around the world. As a scientist, he managed translational biomarker work for several approved drugs including Remicade, Stelara, Infliximab and Spravato.